Predicted protein targets (top 11)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CCR8 | P51685 | 3/20 | 0.61 |
| ▸ | KMT2A | Q03164 | 3/20 | 0.59 |
| ▸ | MEN1 | O00255 | 2/20 | 0.59 |
| ▸ | MGLL | Q99685 | 1/20 | 0.59 |
| ▸ | KDM4E | B2RXH2 | 3/20 | 0.59 |
| ▸ | ALOX15 | P16050 | 1/20 | 0.59 |
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.57 |
| ▸ | GAA | P10253 | 1/20 | 0.57 |
| ▸ | TDP1 | Q9NUW8 | 1/20 | 0.57 |
| ▸ | PKM | P14618 | 1/20 | 0.55 |
| ▸ | KCNH2 | Q12809 | 1/20 | 0.54 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL6505465 | 0.96 | CCR8 (0.58) | CCR8KMT2AMEN1MGLLKDM4E | |
| SCHEMBL6509295 | 0.94 | CCR8 (0.68) | CCR8KMT2AMEN1MGLLKDM4E | |
| SCHEMBL6496404 | 0.91 | MEN1 (0.67) | CCR8KMT2AMEN1MGLLKDM4E | |
| SCHEMBL6500464 | 0.91 | KMT2A (0.63) | CCR8KMT2AMEN1MGLLKDM4E | |
| SCHEMBL6504122 | 0.91 | MEN1 (0.72) | CCR8KMT2AMEN1MGLLKDM4E | |
| SCHEMBL6495946 | 0.90 | CCR8 (0.64) | CCR8KMT2AMEN1MGLLKDM4E | |
| SCHEMBL6530613 | 0.89 | CCR8 (0.60) | CCR8KMT2AMEN1MGLLKDM4E | |
| SCHEMBL6499197 | 0.87 | MEN1 (0.59) | CCR8KMT2AMEN1MGLLKDM4E | |
| SCHEMBL6499179 | 0.87 | MEN1 (0.67) | CCR8KMT2AMEN1MGLLKDM4E | |
| SCHEMBL6505553 | 0.87 | CCR8 (0.70) | CCR8KMT2AMEN1MGLLKDM4E |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20050143372-A1 | Compounds, pharmaceutical compositions and methods of use therefor | MILLENNIUM PHARMACEUTICALS, INC. | 2005-06-30 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20050143372-A1 | Compounds, pharmaceutical compositions and methods of use therefor | CCR8, CCL11, CCR5 | CCR8 1/4885KMT2A 4477/4885MEN1 3088/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.